Search in:

Advanced search

OncoTargets and Therapy Volume 10, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

Qiqi Liu1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan

Pingping Hu1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan

Guodong Deng1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan

Jingxin Zhang2 Division of Oncology, Department of Graduate, Weifang Medical College, Weifang

Ning Liang1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan

Jian Xie1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, Jinan

Lili Qiao3 Department of Oncology, The Fifth People’s Hospital of Jinan, Jinan

Hui Luo4 Department of Radiation Oncology, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China

Jiandong Zhang1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Shandong University, JinanCorrespondence[email protected]

show all

Pages 2147-2154 | Published online: 12 Apr 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
PubMed Web of Science ®Google Scholar
KochMAThomasKRPerdueNRSmigielKSSrivastavaSCampbellDJT-bet (+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2Immunity201237350151022960221
PubMedGoogle Scholar
YuHMYangJLJiaoSCWangJDLiYTGF-beta1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancerJ Huazhong Univ Sci Technolog Med Sci2014341515824496679
PubMedGoogle Scholar
PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
PubMed Web of Science ®Google Scholar
TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
PubMed Web of Science ®Google Scholar
GunturiAMcDermottDFPotential of new therapies like anti-PD1 in kidney cancerCurr Treat Options Oncol201415113714624504486
PubMed Web of Science ®Google Scholar
BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
PubMed Web of Science ®Google Scholar
OaksMKHallettKMCutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid diseaseJ Immunol2000164105015501810799854
PubMed Web of Science ®Google Scholar
LaurentSCarregaPSaverinoDCTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functionsHum Immunol2010711093494120650297
PubMed Web of Science ®Google Scholar
WongCKLitLCTamLSLiEKLamCWAberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosusRheumatology200544898999415870153
PubMed Web of Science ®Google Scholar
PurohitSPodolskyRCollinsCLack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypesJ Autoimmune Dis20052816259622
PubMedGoogle Scholar
WangXBKakoulidouMGiscombeRAbnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequenceJ Neuroimmunol20021301–222423212225905
PubMed Web of Science ®Google Scholar
SaverinoDBrizzolaraRSimoneRSoluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulationClin Immunol2007123219019817321799
PubMed Web of Science ®Google Scholar
DewanMZGallowayAEKawashimaNFractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibodyClin Cancer Res200915175379538819706802
PubMed Web of Science ®Google Scholar
DemariaSKawashimaNYangAMImmune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancerClin Cancer Res200511Pt 272873415701862
PubMedGoogle Scholar
EdgeSBComptonCCThe American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol20101761471147420180029
PubMed Web of Science ®Google Scholar
SatoSFujimotoMHasegawaMSerum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosisRheumatology (Oxford)200443101261126615266059
PubMed Web of Science ®Google Scholar
OaksMKHallettKMPenwellRTStauberECWarrenSJTectorAJA native soluble form of CTLA-4Cell Immunol2000201214415310831323
PubMed Web of Science ®Google Scholar
LiuMFWangCRChenPCFungLLIncreased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosusScand J Immunol200357656857212791095
PubMed Web of Science ®Google Scholar
LinsleyPSGreeneJLBradyWBajorathJLedbetterJAPeachRHuman B7–1 (CD80) and B7–2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity1994197938017534620
PubMed Web of Science ®Google Scholar
SaverinoDSimoneRBagnascoMPesceGThe soluble CTLA-4 receptor and its role in autoimmune diseases: an updateAuto Immun Highlights201012738126000110
PubMedGoogle Scholar
RoncellaSLaurentSFontanaVCTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factorCancer Immunol Immunother201665890991727207606
PubMed Web of Science ®Google Scholar
GrohmannUOrabonaCFallarinoFCTLA-4-Ig regulates tryptophan catabolism in vivoNat Immunol20023111097110112368911
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Soluble cytotoxic T-lymphocyte antigen 4: a favorable predictor in malignant tumors after therapy

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date